

Claims:

1. A composition comprising:

- (a) a Chlamydia infection inhibiting amount of a molecule that interacts with  
mannose-6-phosphate, mannose-6-phosphate receptor or insulin-like  
growth factor-2; and  
(b) a pharmaceutically acceptable carrier, diluent or excipient.

2. The composition of claim 1, wherein said molecule is an antibody.

3. The composition of claim 2, wherein said antibody specifically binds to mannose-  
6-phosphate.

4. The composition of claim 2, wherein said antibody specifically binds to a  
mannose-6-phosphate receptor.

5. The composition of claim 2, wherein said antibody specifically binds to insulin-  
like growth factor-2.

6. The composition of claim 4, wherein said antibody binds to the mannose-6-  
phosphate binding site.

7. The composition of claim 4, wherein said antibody binds to the insulin-like  
growth factor-2 binding site.

8. The composition of claim 1, wherein said molecule comprises mannose-6-  
phosphate.

9. A method of reducing infectivity of Chlamydia comprising administering to a host  
exposed to Chlamydia, a composition comprising a molecule that interacts with  
mannose-6-phosphate, mannose-6-phosphate receptor or insulin-like growth  
factor-2 to reduce Chlamydia infectivity.

10. The method of claim 9, wherein said molecule is an antibody.

11. The method of claim 9, wherein said antibody specifically binds to mannose-6-phosphate.

12. The method of claim 9, wherein said antibody specifically binds to a mannose-6-phosphate receptor.

5 13. The method of claim 9, wherein said antibody specifically binds to insulin-like growth factor-2.

14. The method of claim 12, wherein said antibody binds to the mannose-6-phosphate binding site.

10 15. The method of claim 12, wherein said antibody binds to the insulin-like growth factor-2 binding site.

16. The method of claim 9, wherein said molecule comprises mannose-6-phosphate.